1. Page avancée | 2016.09.19

   Pasteur courses old

   Due to the exceptional circumstances of the Covid-19 health crisis,we are obliged to cancel all Pasteur courses until July 2020 (included).Registrations for Pasteur courses from September 2020 will be open in few days.We apologize for this rescheduling and are waiting for you in our Education Center at the start of the 2020 academic year.With sessions on theory and hands-on practicals, the...

2. Article | 2020.06.16

   Generation of animal models sensitive to SARS-CoV-2 to test vaccines or drugs

   Aim: Rapid development of animal models is of utmost importance to test the efficacy of vaccines and drug against COVID-19. The aim of this research project is to propose models whose cells express the human ACE2 proteins (huACE2) so that they are sensitive to SARS-CoV-2. The ACE2 protein is the gateway for the virus to enter cells. Researchers are proposing to use adenoviruses and...

3. Article | 2020.06.16

   Descriptive study: epidemiological, clinical and immunological analysis of SARS-CoV-2 cases in the Metropolitan Region of São Paulo, Brazil

   Aim: to identify and analyze the profile of people infected with the SARS-CoV-2 virus in São Paulo, Brazil. This project will be conducted in the Metropolitan Region of São Paulo, one of the most densely populated areas in the world, where the contact rate is accordingly high. By studying epidemiological, clinical and serological aspects of infected individuals, this work will supplement...

4. Article | 2020.06.22

   Urgent Discovery of Drug Candidates That Target Coronavirus SARS-CoV-2

   Aim: rapidly provide drug candidates to treat victims of Covid-19. We will do this by applying our cutting-edge technologies and libraries to screen for viable active compounds that kill coronavirus. The strategy will employ phenotype screens (FPDD) that test for coronavirus inhibition using mouse (MHV-59) and human (OC43) virus as models for fast compound screening in cell culture. Direct-...

5. Article | 2020.06.22

   A zebrafish model to study SARS-CoV-2 neuroinvasion

   Aim: Invasion of the central nervous system, possibly via the olfactory nerve, is suspected to play a role in respiratory failure of Covid-19 patients. This project aims to test SARS-CoV- 2 neuroinvasiveness in vivo in a zebrafish model. The zebrafish larva allows easy visualization of the entire nervous system in vivo or with whole mount fixed samples. It could provide a cheap, genetically...

6. Document de presse | 2022.12.13

   Epidemics, pandemics: a never-ending story? – a look back at the conference held on December 7, 2022

   In connection with the bicentenary of Louis Pasteur’s birth, a conference entitled "Epidemics, pandemics: a never-ending story?" was held on Wednesday December 7 at the Institut Pasteur under the high patronage of the French President, Emmanuel Macron. The conference marked the end of a year of events highlighting not only the importance of research in tackling infectious diseases, but also the...

7. News | 2021.03.24

   World Tuberculosis Day: ERA4TB accelerating the development of new treatment regimens

   ERA4TB (the European Regimen Accelerator for Tuberculosis) is a 6-year public-private partnership with a total budget of over €200M that began in 2020 with the goal of accelerating the development of new treatment regimens for tuberculosis (TB). As part of the Innovative Medicines Initiative, ERA4TB brings together experts from academia and pharma, led by Stewart Cole (Institut Pasteur) and David...

8. Document de presse | 2022.12.14

   SARS-CoV-2: improving treatment for patients with a severe infection

   Inflammatory responses to SARS-CoV-2 vary hugely from one individual to the next. Physicians and scientists from the Institut Pasteur, St. James's Hospital in Dublin and Trinity College Dublin have identified factors of increased vulnerability to COVID-19 in some people, which could guide the development of new therapeutic strategies. In particular, the scientists discovered a link between severe...

9. News | 2022.12.07

   SpikImm receives a major funding to accelerate the clinical and industrial development of its monoclonal antibodies against SARS-CoV-2

    SpikImm, a biotech company founded in 2021 by Truffle Capital in collaboration with the Institut Pasteur, has been awarded a €15 million non-dilutive financing from the French governmentFrance  2030 program for its "PROPHYMAB" project, which is supported as part of the "Emerging Infectious Diseases and CBRN Threats" Acceleration Strategy.  SPK001, the first treatment candidate (...

10. Fiche maladie | 2018.12.05

    Cystic fibrosis

    Cystic fibrosis is the most common severe hereditary genetic disease in the Caucasian population. It is an autosomal recessive inherited disease of the CFTR gene. This fatal condition is characterized by respiratory impairment that affects approximately one in every 2,500 births in Europe and North America. Although the life expectancy of affected individuals has risen considerably since the...

Pages